Coagulation Factors Market Size, Share, Growth, and Industry Analysis, By Type (plasma-derived & recombinant) by application, (pharmacy & hospital), and Regional Forecast to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

COAGULATION FACTORS MARKET OVERVIEW

The global Coagulation Factors Market market is starting at an estimated value of USD 15.12 Billion in 2026, on track to hit USD 24.92 Billion by 2035, growing at a CAGR of 5.8% between 2026 and 2035.

Coagulation Factors market involves the products which are utilized to treat bleeding disorders which include haemophilia A, haemophilia B, von Will brand disease, and other deficiencies of the clotting factors. These are either plasma-derived or recombinant factors which assist in restoring normal blood clotting and avoiding unnecessary blood loss during trauma, during surgery or during normal activity. The increased understanding of genetic disorders, the development of biotechnology, and the growing accessibility of prophylactic treatment are changing the way to care about patients. One of the biggest drivers in the market is the replacement of plasma-based factors by safer and more effective recombinant and long-acting factors. Increased expenditures in healthcare across the globe, screening of new-borns, and better diagnostic abilities are also contributing to the level of demand. Moreover, the long-term growth trajectory in the market is being influenced by increasing the access to treatment in the developing economies and continuing innovation in the fields of gene therapy and long half-life products.

COVID-19 IMPACT

Pandemic hindered the market growth due to temporary shortages in plasma-derived coagulation factors and postponed elective treatment

The covid 19 pandemic impact the coagulation factors market growth. At the beginning of the pandemic, supply chains, blood donation and hospital activities were disrupted, which resulted in temporary shortages in plasma-derived coagulation factors and postponed elective treatment. Lockdowns and minimized hospital visits affected many patients with bleeding disorders by limiting their access to regular health care and surveillance, as well as prophylaxis and therapy. However, the recombinant and home-based coagulation therapies had a rise in demand as patients moved on the self-administration to avoid the clinical environment. Studies also contributed to the importance of abnormal coagulation in the extreme COVID-19 cases, increasing the level of awareness in the state of clots-related disorders. The market also bounced back as healthcare systems stabilised, fuelled by the adoption of new treatments, enhanced supply chains, and increased demand of safer long-acting recombinant products.

LATEST TRENDS

Recombinant technologies and customized medicine to be prominent trends

The coagulation factors market is undergoing remarkable developments that are informed by the innovation in the recombinant technologies and customized medicine. There is the growing popularity of long-acting coagulation factor, such as PEGylated and fusion-protein products, which are less frequently dosed, and are more patient-compliant. Gene therapy is becoming a ground breaker trend, the current clinical trials involving haemophilia A and B have positive outcomes and it might lessen or eradicate the necessity of routine factor replacement in the body. Moreover, non- factor therapies (bispecific antibodies and RNA-based treatments) are increasingly used and provide both efficient prophylaxis and a reduced number of complications. Patients are being managed by use of digital health tools such as remote monitoring systems and home-care delivery systems. Further shifts in the future direction of the market are caused by the increasing attention to safety, decreased immunogenicity and cost-effective biosimilar.

COAGULATION FACTORS MARKET SEGMENTATION

By Type

Based on type, the global market can be categorized into plasma-derived & recombinant.

• Plasma-derived: Coagulation factors derived through plasma are removed out of the donated human plasma and applied to the treatment of bleeding conditions. They are still invaluable in areas that lack access to recombinant products, with effective and low-cost therapy despite concern of pathogen-transmission.

• Recombinant: Genetic engineering is used to produce recombinant coagulation factors which are high purity, safe and lower risk of infection. They offer good and consistent therapeutic use in haemophilia, and they are becoming more preferred because of the long-acting formulations and uninterrupted supply.

By Application

Based on application, the global market can be categorized into pharmacy & hospital.

• Pharmacy: Coagulation factor products are provided in pharmacies to be used at home, thus making it convenient to patients with chronic bleeding disorders to manage. They advocate home-based therapy, enhancements in the rates of treatment compliance, persistence of care, and the general quality of life of haemophilia patients.

• Hospital: Hospitals are one of the key end users of coagulation factors, which are required to control bleeding in case of emergency, surgery, trauma, and severe haemophilia cases. They guarantee high-rate administration, expert care, and a higher level of monitoring of the complex or high-risk patients.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.        

Driving Factors

Increase in the numbers of bleeding disorders to increase the market growth

One of the most powerful forces behind the market of coagulation factors is the increase in the numbers of bleeding disorders. Haemophilia A (Factor VIII deficiency), haemophilia B (Factor IX deficiency) and von Will brand disease are increasingly being diagnosed because of improved genetic testing, increased clinical awareness, and increased new-born screening programs. Due to the increased number of cases of patients diagnosed early, there is an upward trend in the demand of the factor replacement therapies. In addition, it has been found that more patients with chronic bleeding conditions have survived, which has resulted in more patients needing long-term or on-demand prophylaxis treatment. Increasing awareness of the developing nations, as well as the increasing access to healthcare, is also driving more cases being diagnosed. All this has a tremendous effect in increasing the demand of plasma-derived and recombinant coagulation factor products.

Non-haemophilia clinical environment to increase the market growth

Market is growing at a significant rate due to the increasing application of coagulation factors in the non-haemophilia clinical environment. These products are currently being largely used in surgical, trauma treatments, and organ transplants to manage effectively the acute bleeding complications. Patients in large surgical procedures, including cardiovascular, orthopaedic, and liver surgeries, can experience the risk of bleeding a lot, and this is why hospitals need to use factor concentrates to achieve rapid haemostasis. Coagulation factors are also used in trauma centres to heal life-threatening bleeding because of accident or injury where rapid clotting of the blood is necessary. Moreover, the coagulation support is often necessary because of the impaired liver functioning in organ transplant patients whose liver functions regulate the natural factors production. The use of coagulation factors in the expanded clinical settings is on the increase, as global surgical volumes continue to grow with the increase in the trauma cases, creating market demand.

Restraining Factor

Threat of the emergence of inhibitors to limit the market growth

The threat of the emergence of inhibitors is also a major limitation in the coagulation factors market. Factor IX inhibitors can develop in many patients, especially haemophilia a patients who are undergoing Factor IX replacement therapy, which consists of the clotting factor being infused back into the body. Such immune response causes resistance of normal treatment resulting in uncontrolled bleeding episodes and increased morbidity. Inhibitors are difficult to control, and costly to an extent that they may necessitate bypassing of agents, immune tolerance induction therapy or newer non-factor options. The treatments add additional weight to the health care systems and restrict patient access particularly in cost-sensitive areas. Long-term management of the disease is also made difficult by the existence of inhibitors and confidence in clinicians in traditional factor therapies is blocked. The increasing trend in the number of inhibitors poses an enormous problem, which puts off some patients and providers the complete trust in the factor replacement therapies, and leaves the success of treatment uncertain.

Field of biotechnology and increasing healthcare access in the world to opportunity in the market

Opportunity

The future of the coagulation factor market is great because of the developments in the field of biotechnology and increasing healthcare access in the world. One of the largest growth opportunities is provided by gene therapy, without which haemophilia may have long-term or curative solutions, which will eliminate the need to infuse on a regular basis. Further improvements of extended half-life recombinant factors will also result in more convenience and adherence. The increasing need in the emerging markets, which is assisted by the increased diagnostics and government spending on the treatment of rare diseases, will lead to new sources of revenues.

In addition, the emergence of home-based treatment, electronic tracking devices, and biosimilar will widen affordability and access, generating immense market increasing opportunities over the long-term.

Treatment process difficult and enhance the health care burden could be a potential challenge

Challenge

These are some of the main challenges that will be encountered in the coagulation factors market in future. The recombinant/advanced therapies such as gene therapy are expensive and therefore may not be widely used particularly in the developing regions. Formation of the inhibitors will continue being a significant clinical problem that will make the treatment process difficult and enhance the health care burden. The existence of new non-factor therapeutics and long-acting biologic therapies could lessen the use of conventional factor products. Regulatory obstacles, high standards of manufacture and supply of plasma can also curtail market growth.

Besides, the differences in healthcare infrastructure and inaccessibility to diagnostic facilities in low-income countries will complicate the process of guaranteeing the consistency and fair treatment of each patient.

•   
•   
  Download Free Sample to learn more about this report

    

COAGULATION FACTORS REGIONAL INSIGHTS

North America

The North America dominates the coagulation factors market share due to the development of the healthcare infrastructure, good diagnostic abilities, and the high sensitivity of bleeding disorders. The U.S. coagulation factors market is the leader in the region, which is backed by substantial number of patients with haemophilia a, haemophilia B as well as von Will brand disease. Large availability of recombinant and plasma-derived coagulation therapies and robust reimbursement models hastens the uptake of treatment. Market leadership is also enhanced by the existence of large biopharmaceutical firms, ongoing research and development efforts and the uninterrupted approval of products. Moreover, the U.S. emphasizes an early diagnosis and preventive treatment, which puts more strain on prophylaxis factor therapies. Increasing investments in gene therapy research, hi-tech production, and national centres of haemophilia treatment are firm foundations of the domination of North America in the world market of coagulation factors.

Europe

Europe is a formidable competitor in the coagulation factor market that can be explained by developed healthcare, systematic treatment regimens, and the general availability of specialized care of bleeding disorders. Germany, U.K., France and Italy are the leading countries in demand because the countries have well established haemophilia centres and have extensive reimbursement policies in regards to recombination and plasma-derived factor therapies. The area is also characterized by a good regulatory regulation under the European Medicines Agency (EMA), which provides high quality of treatment options and innovation. The continued clinical trials, increased use of long-acting factor products and early adoption of gene therapy further enhances market growth. In addition, the growing attention of Europe to the problem of managing rare diseases, patient registries, and nationwide screening programs keeps increasing the rate of diagnosis and coverage of treatment, which facilitates the stable growth of the coagulation factors market.

Asia

The market of the Asia Pacific coagulation factors is rapidly growing due to the expansion of healthcare infrastructure, the increase of the rate of haemophilia and other bleeding disorder diagnosis and the rise of the governmental aid in the management of the rare diseases. China, Japan, India, and South Korea are all making investments in more progressive biologics and recombinant factor therapy in a bid to stop relying on plasma-derived products. The treatment is also increasing with the expansion of health insurance coverage and increased awareness of physicians and patients. The technological development is the highest in Japan and South Korea, and China is rising rapidly in domestic production to enhance affordability. Although the treatment of coagulation factors faces difficulties such as high therapy costs and lack of equity in rural locations, the vast population base in the region, the increasing clinical capacities and the government-supported treatments regimes are driving the vigorous long-term growth of the coagulation factors market.

KEY INDUSTRY PLAYERS

Key Players have a powerful influence on the tendencies and trends of the market, technological development

An effective team of international pharmaceutical and biotechnological firms that focus on haematology and rare disease therapies motivates the coagulation factors industry. The major players are CSL Behring, Takeda Pharmaceutical Company, Pfizer, Bayer, Octapharma, Novo Nordisk and Grifols and each of them possesses a wide range of products of plasma-derived and recombinant coagulation factors. These are firms that greatly emphasize on innovation, growth of manufacturing, and enhancing safety and efficacy of factor therapies. They have expertise in high recombinant technologies, long half-life formulations and new gene therapy systems. There are strategic collaborations, R&D investment, and development of clinical contributions that assist these players to meet the unexpressed need in haemophilia and other bleeding disorders. Having good distribution networks around the world and experience in regulation, these businesses have a powerful influence on the tendencies and trends of the market, technological development, and the competitive situation in the industry as a whole.

List Of Top Coagulation Factors Companies

• Takeda (Japan)
• Octapharma (Switzerland)
• Pfizer (U.S.)
• Bayer (Germany)
• NovoNordisk (Denmark)
• CSL (U.S.)
• Grifols (Spain)

KEY INDUSTRY DEVELOPMENT

November 2023: Ethicon, a Johnson and Johnson company that specializes in MedTech, gave its approval to ETHIZIA, a new generation haemostatic sealing patch used to prevent bleeding of difficult-to-reach surgical areas. The first haemostat ever with a special synthetic polymer technology is ETHIZIA, which provides consistent performance on both sides of the patch and increases the efficiency of the surgery. The solution offers quick, dependable bleeding management, which reinforces better patient outcomes and increases Ethicon product line of innovative surgical care.

REPORT COVERAGE   

The report will be of great value to the coagulation factors manufacturers, the new entrants in the market and the companies in the overall industry chain. It provides specific information on revenues, volume of sales and average prices, which allows businesses to evaluate performance in the market and detect areas of growth. The report assists the stakeholders in the demands and competitive positioning by disaggregating information amongst different segments; that is, product types (plasma-derived or recombinant), applications (use in hospitals or pharmacies) and geographies (regions). This data allows the companies to refine production strategies, optimize pricing and market expansion planning. The new entrants will get an insight on where they can enter and what the major competitors are, and the supply chain partners will be able to assess the trends that can affect the raw material requirements, and distribution demands. Overall, the report will assist in strategic decision-making, investment planning, and long-term market forecasting.